Are Wegovy, Zepbound and Mounjaro still in shortage? What the FDA database says

“Is Wegovy still hard to get?” is one of those questions where the answer you get depends entirely on who you ask. Your pharmacist has a view. A Reddit thread has forty views. There is, though, one place that is the actual record: the FDA’s Drug Shortages database. It is public, it is searchable, and it is not especially hard to read once you know what the labels mean.

So here is what the database says, what the FDA’s own statements say about how each shortage ended, and what that does and does not mean for you standing at a pharmacy counter being told they have none.

How the database actually works

You search it by generic name or active ingredient — semaglutide, tirzepatide, liraglutide — rather than by brand. Wegovy and Ozempic are both semaglutide. Zepbound and Mounjaro are both tirzepatide. Saxenda is liraglutide. Searching the brand name will not find the entry.

Entries fall into three buckets. Currently in shortage means exactly that. Resolved means, in the database’s own framing, that the market is covered based on the information manufacturers have supplied — while noting that some individual presentations may still be unavailable. Discontinuations is a separate category again, for products a manufacturer has permanently withdrawn and reported under section 506C, where six months’ advance notice is preferred for life-supporting or life-sustaining drugs.

The gap between those buckets and your local pharmacy is worth naming. The database is built from what manufacturers report about national supply. It is not a stock check. A drug can be listed as resolved nationally while the specific dose of the specific pen you are on is not in the shop you walked into. Both things are true at once, and only one of them is what the database is measuring.

Where Zepbound, Mounjaro, Wegovy and Ozempic stand

Both molecules spent a long stretch on the shortage list, and both came off it. The FDA determined the tirzepatide injection shortage resolved on 19 December 2024. It determined the semaglutide injection shortage resolved on 21 February 2025. Those dates cover the molecules, which is why they cover Zepbound and Mounjaro together, and Wegovy and Ozempic together — the database does not track brands separately.

Checking the database on 4 September 2026 for this guide, neither semaglutide injection nor tirzepatide injection appeared as a current shortage. That is consistent with the resolution dates above, and with the FDA’s compounding statement — updated 1 April 2026 — which sets out the dates after which compounders could no longer rely on shortage status.

What the resolution dates do not tell you is how smooth any given month has been at pharmacy level, or whether a particular dose in the titration ladder is easy to get. Those are local questions the national record was never designed to answer.

Liraglutide sits slightly apart. It is the active ingredient in Saxenda, a daily injection rather than a weekly one, and the FDA named it alongside semaglutide and tirzepatide in its April 2026 proposal about compounding — so if you are checking the database for a daily injectable, search liraglutide, not the brand.

Checking it yourself is worth the minute. The database has separate views for current shortages, discontinuations and recent updates, and you can search it by active ingredient or browse by therapeutic category. If someone tells you a drug is or is not in shortage, that page settles it, and it is the same page the pharmacy and the prescriber are working from.

Why a “resolved” listing changed the whole market

A shortage listing is not just an information service. It is a legal switch. Compounding pharmacies can generally make copies of a commercially available drug when that drug is in shortage — which is the footing the whole compounded GLP-1 market stood on. The FDA states the consequence directly: when a shortage is resolved, “FDA generally considers the drug to be commercially available”, and the usual restrictions on making essentially a copy apply again.

For semaglutide, the agency set transition dates — 22 April 2025 for state-licensed pharmacies under section 503A, and 22 May 2025 for outsourcing facilities under section 503B. Then on 30 April 2026 the FDA proposed to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, saying it “did not identify sufficient evidence” of clinical need, with comments open until 29 June 2026. Its explanation of why that list matters is the clearest single sentence on the topic: in most cases outsourcing facilities cannot compound from a bulk substance “unless the substance appears on the 503B bulks list, or the compounded drug is on the FDA’s drug shortage list at the time of compounding, distribution, and dispensing”.

If you are trying to work out why the cheap telehealth offer you saw in 2024 has vanished, that is the answer, and it traces back to two dates on a government database. There is more detail in the compounded versus brand guide.

If your pharmacy has none anyway

A national resolution is cold comfort at the counter. These are the practical avenues, in the order most people find useful.

One route people ask about is going back to a compounded version while they wait. The FDA’s framing is that a compounded drug “might be appropriate if a patient’s medical need cannot be met by an FDA-approved drug, or the FDA-approved drug is not commercially available” — and its advice to patients is to get a prescription from a doctor and fill it at a state-licensed pharmacy. The rest of that picture, including what the agency has recorded about compounded products, is in the companion guide.

The wider point: there are more doors now

The 2022–2024 shortages happened when there were essentially two GLP-1 injections everyone wanted. The map is different now. There is an oral semaglutide pill, and there is Foundayo, a daily tablet approved in 2026 — neither of which is an injectable pen. Whether any of them suits a given person is a clinical question, and the comparison tool lays the approved options side by side on the trial numbers rather than on availability.

And if supply is what forces a change of plan rather than choice, the switching page covers what moving between treatments involves. Check the database first, though. It takes a minute, and it settles the argument.